MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c)
PeptideThe community score (58) substantially exceeds the medical score (22) — the user community reports considerably more positive experiences than the clinical evidence base justifies [c1, s1].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
MOTS-c is a mitochondrially encoded peptide with compelling preclinical data on insulin sensitivity, fat loss, and endurance — but not a single RCT has investigated exogenous MOTS-c therapeutically in humans. Use outside clinical trials is illegal in Germany, listed on the WADA prohibited list, and carries significant quality and safety risks. Community reports are largely anecdotal and unverifiable. Anyone considering MOTS-c should be fully aware of the legal consequences, the absence of dosing standards, and a completely uncharacterised long-term risk profile.
Description
MOTS-c is a 16-amino acid peptide encoded by mitochondrial DNA that acts as a metabolic regulator and exercise mimetic.
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide considered the first identified metabolically active peptide encoded by the mitochondrial genome. It was first described in 2015 by Dr. Changhan David Lee and Pinchas Cohen at the USC Leonard Davis School of Gerontology. Unlike most therapeutic peptides encoded by nuclear genes, MOTS-c originates in the mitochondria. It acts as a systemic, endocrinologically active mitokine, circulating in the blood as a hormone primarily produced and released by skeletal muscle. MOTS-c levels rise naturally during physical exertion and stress, but decline with age and in metabolic disease. Preclinical studies demonstrate that MOTS-c improves insulin sensitivity, promotes fat oxidation, enhances glucose uptake, and slows age-related physical performance decline. These properties have led to MOTS-c being termed an "exercise mimetic," as it can elicit effects similar to physical training. In animal models, MOTS-c administration prevented diet-induced obesity and improved metabolic health without changes in food intake or physical activity. Additional research areas include the role of MOTS-c in osteoporosis (supporting bone metabolism), neuroprotection, cardiovascular health, inflammation modulation, and radioprotection. Initial human data from pilot studies suggest improvements in metabolic markers in insulin-resistant patients; however, large-scale clinical trials are lacking to date. As of April 2026, the FDA is evaluating MOTS-c for inclusion in the Section 503A bulk drug substances list, with obesity and osteoporosis being assessed as specific indications. Overall, MOTS-c remains an experimental substance whose clinical translation is pending.
Legal Status (DE)
MOTS-c is approved neither as a medicinal product nor as a dietary supplement in Germany or the EU [s13, s14]. The substance is classified as an experimental research peptide without regulatory approval by the EMA or BfArM [s13, s14]. In the EU, MOTS-c may not be marketed as a food, dietary supplement, or remedy, as it holds no novel food authorization and is not listed on the positive list of permitted dietary supplement ingredients [s13, s14]. In the United States, the FDA classifies MOTS-c as an investigational substance; no approval for human use exists, and compounding pharmacies are prohibited from preparing MOTS-c formulations [s13, s14]. WADA (World Anti-Doping Agency) has classified MOTS-c as a prohibited substance under the categories of AMPK activators and metabolic modulators, making its use in competitive sports categorically prohibited [s13, s14]. Acquisition for purely scientific research purposes exists in a legal grey area; sale with health-related claims or for self-administration is illegal [s13, s14].
Mechanism of Action
MOTS-c exerts its biological effects through several interconnected signaling pathways: 1. Folate-AICAR-AMPK axis: MOTS-c disrupts the intracellular folate-methionine cycle, thereby increasing concentrations of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous AMP analogue. AICAR subsequently activates AMPK (AMP-activated protein kinase), the cell's central energy sensor. AMPK enhances glucose uptake, inhibits anabolic and energy-consuming processes, and promotes fat oxidation and mitochondrial biogenesis. 2. Nuclear translocation: Under metabolic stress or physical exertion, MOTS-c translocates from the cytosol to the cell nucleus, where it directly regulates the expression of stress-related genes containing antioxidant response elements (ARE). Regulated target genes include GLUT4 (glucose transporter), STAT3, IL-10, and additional stress response genes. 3. Nrf2 activation: MOTS-c increases Nrf2 (Nuclear Factor Erythroid 2-Related Factor 2) levels and promotes its nuclear translocation, resulting in upregulation of antioxidant defense mechanisms and reduction of oxidative stress. 4. Mitochondrial quality control: MOTS-c activates mitochondrial fusion and mitophagy signaling pathways, thereby improving mitochondrial quality and functional capacity. It inhibits the mitochondrial respiratory chain (Complex I), contributing to AMPK activation and increased metabolic flexibility. 5. Inflammation modulation: By reducing MAPK phosphorylation, inhibiting pro-inflammatory cytokines such as IL-6 and IL-1β, and promoting IL-10, MOTS-c exerts anti-inflammatory effects. 6. Regulation of bone metabolism: MOTS-c influences the balance between osteoblast and osteoclast activity, potentially exerting a protective effect in osteoporosis. In summary, MOTS-c acts as a mitochondrial-nuclear retrograde signal that coordinates cellular energy homeostasis, metabolic stress adaptation, and tissue protection.
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Reaktionen an der Injektionsstelle (Rötung, Schwellung, Schmerz, Juckreiz) Typical local reactions to subcutaneous peptide injections; not specific to MOTS-c. The CB4211 analogue showed persistent, painless induration at the injection site in phase 1 studies. | gelegentlich | leicht |
| Appetitverlust oder Appetitveränderungen Mechanistically plausible via AMPK activation, which influences satiety and energy-regulatory signaling pathways. | gelegentlich | leicht |
| Energieschwankungen / Müdigkeit Due to shifts in cellular energy metabolism (glucose vs. fat oxidation); typically transient during the adaptation phase. | gelegentlich | leicht |
| Leichte gastrointestinale Beschwerden (Übelkeit, Bauchunbehagen) Reported sporadically; likely mediated indirectly via metabolic signaling pathway alterations. | gelegentlich | leicht |
| Kopfschmerzen Reported anecdotally; possible association with vascular or metabolic adjustment reactions. | selten | leicht |
| Erhöhte Herzfrequenz / Herzrasen Reported from self-experiments according to USADA; possible cause is increased sympathetic activation due to elevated energy expenditure. | selten | moderat |
| Schlaflosigkeit Reported anecdotally; possibly caused by adaptations in mitochondrial energy metabolism or cortisol interactions. | selten | leicht |
| Fieber Reported from self-experiments; mechanism unclear, possibly an immunomodulatory reaction. | selten | leicht |
| Hypoglykämie (niedriger Blutzucker) Theoretical risk due to AMPK activation and increased glucose uptake, particularly with concomitant use of blood glucose-lowering medications, fasting, or calorie-restricted diet. | theoretisch | moderat |
| Theoretische Auswirkungen auf die Zellproliferation / Krebsrisiko Conflicting data: antitumor properties are discussed on one hand, while theoretical concerns exist regarding potential promotion of prostate and breast cancer through modulation of cellular proliferation and metabolic pathways. No clinical evidence; caution warranted in active malignancy. | theoretisch | schwer |
Contraindications
No safety data available for pregnant or breastfeeding women; potential effects on fetal/neonatal development unknown. Absolute contraindication.
Peptide allergies can trigger severe anaphylactic reactions.
Conflicting data regarding tumor-promoting vs. antitumoral effects; insufficient safety data in patients with active malignancy. Use without medical consultation not recommended.
No pharmacokinetic or safety data available for patients with severe renal or hepatic disease; unpredictable risk profile.
MOTS-c improves insulin sensitivity and may reduce insulin requirements; insulin dose adjustment and close medical monitoring are required to prevent hypoglycemia.
Improvements in insulin sensitivity may initially destabilize diabetes management; stabilization of blood glucose levels prior to use is recommended.
Thyroid dysfunction may unpredictably alter the metabolic risk profile under MOTS-c.
Interactions
Synergistic
No primary study on the combination of MOTS-c and exendin-4 identified. Evidence level downgraded from 'rct' to 'preclinical_hypothetical' until a primary source is available.
Humanin and MOTS-c are both mitochondrially encoded peptides with complementary protective functions. Humanin acts primarily as a neuroprotective agent, while MOTS-c regulates peripheral metabolism. Together, they may provide a broad mitochondrial protection profile.
Berberine and MOTS-c both activate the AMPK signaling pathway, thereby improving insulin sensitivity and glucose metabolism. The combination may offer additive metabolic benefits in insulin resistance and obesity.
CoQ10 supports electron transfer in the mitochondrial respiratory chain, providing the structural basis upon which MOTS-c exerts its metabolic signaling effects. The combination may synergistically improve ATP production and antioxidant protection.
Alpha-lipoic acid is a mitochondrial cofactor with antioxidant activity and, in combination with MOTS-c, may reduce oxidative stress in mitochondria. Both compounds demonstrate positive effects on insulin sensitivity and energy metabolism.
PQQ stimulates the biogenesis of new mitochondria (mitochondriogenesis), while MOTS-c optimizes the function of existing mitochondria via AMPK activation. This combination may improve both the quantity and quality of mitochondria.
In preclinical studies, the combination of MOTS-c and exendin-4 (a GLP-1 analogue) showed synergistic effects on the reduction of cellular senescence in pancreatic beta cells. Both compounds complement each other in delaying diabetes-associated beta cell aging.
NMN raises cellular NAD⁺ levels, thereby activating sirtuins and indirectly AMPK. MOTS-c directly activates AMPK and regulates mitochondrial gene expression. Both compounds act complementarily on energy metabolism and mitochondrial health.
Like NMN, nicotinamide riboside elevates NAD⁺ levels and supports mitochondrial energy production. In combination with MOTS-c, a more comprehensive mitochondrial activation may be achieved, as both compounds engage different intervention points in energy metabolism.
Creatine improves ATP resynthesis in muscle and brain cells and, together with MOTS-c, may synergistically enhance metabolic performance and insulin sensitivity in skeletal muscle. Both compounds have been used in mitochondrial protection protocols.
Caution
Despite synergistic AMPK activation, concurrent use of berberine and MOTS-c carries an increased risk of excessive blood glucose lowering, particularly with a low-carbohydrate diet or during fasting. Close blood glucose monitoring is recommended.
Community Evidence
Top reported benefits
- Improved energy levels and reduced afternoon fatigue
- Fat loss / improved body composition (especially visceral fat)
- Increased exercise endurance and athletic performance (exercise mimetic)
- Improved insulin sensitivity and glucose tolerance
- Anti-aging effects / mitochondrial health and longevity
Top reported issues
- Injection site reactions (redness, swelling, hematomas)
- Initial fatigue / transient energy drop in the first few days
- Mild blood glucose fluctuations (dizziness, headaches), especially when taken fasted
- Unclear dosing protocols – widely diverging community recommendations (1 mg to 10 mg)
- Uncertainty regarding product quality and peptide degradation after reconstitution
The community repeatedly warns against combining MOTS-c with other AMPK activators (e.g., metformin, berberine) without medical supervision, as hypoglycemic episodes are possible. Diabetics and individuals with insulin resistance should monitor blood glucose closely. Competitive athletes in tested sports have been prohibited from using MOTS-c since 2024 (WADA prohibited list, category S4.4 – AMPK activators). A single, widely cited Reddit report of dramatic body fat reduction (18% → 15% in 15 days) was classified by the community as an unverified individual anecdote. Concerns about peptide stability after reconstitution are circulating (unconfirmed claim of rapid degradation), prompting some users to inject immediately after reconstitution.
Scientific Sources
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P (2015). Cell MetabolismCPMID:25738459DOI - The mitochondrial-derived peptide MOTS-c promotes homeostasis in aged human placenta-derived mesenchymal stem cells in vitro
Kim SJ, et al. (2021). AgingCPMID:33639272 - Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes
Kong BS, Lee H, L'Yi S, et al. (2025). Experimental & Molecular MedicineCLink - The Mitochondrial-Derived Peptide MOTS-c Alleviates Radiation Pneumonitis via an Nrf2-Dependent Mechanism
Zhu X, et al. (2024). AntioxidantsCLink - MOTS-c Cognitive Vitality Report — Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation (ADDF) (2021). Journal nicht verfügbarBLink - What is the MOTS-c peptide? — U.S. Anti-Doping Agency (USADA)
U.S. Anti-Doping Agency (USADA) (2023). Journal nicht verfügbarBLink - WADA 2025 List of Prohibited Substances and Methods — International Standard
World Anti-Doping Agency (WADA) (2024). Journal nicht verfügbarBLink - Athlete Advisory: What's New on the 2025 WADA Prohibited List — USADA
U.S. Anti-Doping Agency (USADA) (2024). Journal nicht verfügbarBLink - Explanation of Key Changes on the 2024 WADA Prohibited List — USADA
U.S. Anti-Doping Agency (USADA) (2023). Journal nicht verfügbarBLink - FDA Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding
U.S. Food and Drug Administration (FDA) (2023). Journal nicht verfügbarBLink - Key Updates in the WADA 2025 Prohibited List: Implications for Competitive Sports
Marcinkowska J, et al. (2025). Quality in SportBLink - MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C (2021). Nature CommunicationsCPMID:33473109DOI - Peptide Laws in Germany 2026: What's Legal & What's Not
ORYN Peptide Labs (2026). Journal nicht verfügbarDLink - Drug & Medical Device Litigation Laws and Regulations Report 2026 — Germany
ICLG (International Comparative Legal Guides) (2026). Journal nicht verfügbarBLink - CB4211, a Novel Analog of MOTS-c, Improves Markers of Liver Disease and Metabolic Dysfunction in a Phase 1b Clinical Trial for NASH and Obesity
Cundy K, et al. (CohBar, Inc.) (2021). AASLD The Liver Meeting 2021 (Poster LB5)CLink - The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis
Zhou Q, Yin S, Lei X, Tian Y, Lin D, Wang L, Chen Q (2024). Diabetology & Metabolic SyndromeADOI - Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors
Dieli-Conwright CM, et al. (2021). Frontiers in OncologyBLink - The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study
Bolignano D, Greco M, Presta P, Duni A, Zicarelli M, Mercuri S, Pappas E, Lakkas L, Musolino M, Naka KK, et al. (2024). Blood PurificationBPMID:39111290DOI - MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury
Shen Z, Lu P, Jin W, Wen Z, Qi Y, Li X, Chu M, Yao X, Wu M, Wang A, Zhang X, Wang W, Song M, Wang X, et al. (2025). American Journal of Respiratory Cell and Molecular BiologyBPMID:40035775DOI - Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging
Wan W, Zhang L, Lin Y, Rao X, Wang X, Hua F, Ying J (2023). Journal of Translational MedicineBPMID:36670507DOI - MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes
Li X, Zhan F, Qiu G, Lu P, Shen Z, Qi Y, Wu M, Chu M, Feng J, Wen Z, Yao X, Wang A, Jin W, Zhang X, Liao J, Zhang J, Song M, Wang W, Wang X (2025). Redox BiologyCDOI - MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases
Mohtashami Z, Singh MK, Salimiaghdam N, Ozgul M, Kenney MC (2022). International Journal of Molecular SciencesBPMID:36233287DOI
Community Sources
Storage
Unopened
Store lyophilized MOTS-c powder at −20 °C (or below) in a dry, light-protected environment. Preferably store with desiccant to minimize moisture exposure. Shelf life under correct storage conditions: 24–36 months. For short-term use (a few months), refrigerator temperature (2–8 °C) is also acceptable.
Opened
After reconstitution with sterile bacteriostatic water, store at 2–8 °C under refrigeration. Avoid light exposure using aluminum foil or amber glass vials. Use within 7–14 days (optimal potency through day 14; noticeable purity decline from day 30 onward). Note the reconstitution date on the vial. Never freeze reconstituted solution (ice crystal formation irreversibly destroys peptide structure).
Notes
Freeze-thaw cycles must be strictly avoided. Briefly warm lyophilized vials to room temperature before opening to prevent internal condensation. For long-term storage, a carrier protein (0.1% HSA or BSA) may be added.